Attention Pharmacists and Pharmacy Techs: Click to access CPE Monitor and CE information More Information
This activity will review the latest PK recommendations for Factor VIII and IX replacement and how to use and interpret PK parameters to assess treatment plans.
Choose from the criteria below to find an activity that fits you best.
|A product of the Society of Infectious Diseases Pharmacists Education Center (SIDPEC)|
Members from the Society of Infectious Diseases Pharmacists have prepared brief,
evidence-based reviews of potential pharmacotherapeutic treatment options for COVID-19.
These video presentations and handouts will be updated regularly as new data emerges
on each of these experimental therapies. Please note: Data about COVID-19 and potential
treatments is changing at a very rapid pace. Clinicians should use multiple resources
and their professional judgement in making treatment decisions. View www.SIDP.org/COVID19
for the latest video presentations and handouts.
This is a featured CE activity on the Society of Infectious Diseases Pharmacists Education Center (SIDPEC) website. SIDPEC is the educational hub of the Society of Infectious Diseases Pharmacists (SIDP). The SIDPEC portal provides educational activities on infectious disease pharmacotherapy for clinical pharmacists, health‐systems pharmacists, community pharmacists, and other allied‐health disciplines.
The target audience for this activity is pharmacists. At the completion of this CE activity the participant will be able to do the following in regard to specific treatments being considered for COVID-19:
Daniel B. Chastain, PharmD, BCIDP, AAHIVP
Clinical Assistant Professor
University of Georgia College of Pharmacy
Infectious Diseases Pharmacist, Phoebe Putney Memorial Hospital
Release Date: May 26, 2020
Expiration Date: May 26, 2021
This activity is jointly provided by ProCE, Inc. and the Society of Infectious Diseases Pharmacists. ProCE, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-9999-20-296-H01-P has been assigned to this home-study knowledge-based activity. This activity is approved for 0.5 contact hours (0.05 CEU) in states that recognize ACPE providers. The activity is provided at no cost to participants. Completion of the evaluation and the post-test with a score of 70% or higher are required to receive CE credit. No partial credit will be given. Statements of completion will be issued online at www.ProCE.com, and proof of completion will be posted in NABP CPE Monitor profiles.
It is the policy of ProCE, Inc. to ensure balance, independence, objectivity and scientific rigor in all of its continuing education activities. Faculty must disclose to participants any significant financial interest or affiliation with companies that manufacture or market products discussed in this activity. Dr. Chastain has no relevant commercial or financial relationships to disclose.
No external support has been received for this activity.
The material presented in this CE activity does not reflect the views of ProCE, Inc. or the commercial sponsor. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.